Astellas Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.12.22	Astellas Announces Positive Results From Phase 3 Trial Of Zolbetuximab Combination In Gastric Cancer (RTTNews)
16.12.22	Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and... (PR Newswire)
14.12.22	Astellas and MBC BioLabs Announce 2022 Future Innovator Prize Awarded to Bespoke Biotherapeutics and Cellinfinity Bio (PR Newswire)
17.11.22	Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroe... (PR Newswire)
30.10.22	Ausblick: Astellas Pharma legt Zahlen zum jüngsten Quartal vor (finanzen.net)
25.10.22	Astellas Pharma To Support Development Of Taysha's AAV-based Gene Therapy Programs (RTTNews)
25.10.22	Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs (PR Newswire)
16.10.22	Erste Schätzungen: Astellas Pharma verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
12.10.22	Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual Meeting (PR Newswire)
04.10.22	Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming (PR Newswire)
30.09.22	Astellas : EMA Accepts Marketing Authorization Application For Fezolinetant (RTTNews)
30.09.22	European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant (PR Newswire)
20.09.22	Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts (PR Newswire)
12.09.22	Seagen, Astellas, Merck: EV-103 Results Support Investigation Of Enfortumab Vedotin, Pembrolizumab (RTTNews)
12.09.22	Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothe... (PR Newswire)
05.09.22	Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China (PR Newswire)
18.08.22	U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant (PR Newswire)
02.08.22	Astellas Announces Management Structure (PR Newswire)
31.07.22	Ausblick: Astellas Pharma präsentiert Quartalsergebnisse (finanzen.net)
26.07.22	Astellas, Seagen Report Positive Topline Results For Padcev With Keytruda To Treat Urothelial Cancer (RTTNews)
26.07.22	Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer (PR Newswire)
22.07.22	Astellas Unveils Plans to Open New Biotech Campus in South San Francisco (PR Newswire)
17.07.22	Erste Schätzungen: Astellas Pharma stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
05.07.22	Mogrify, Astellas Pharma Announce Research Agreement (RTTNews)
05.07.22	Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss (PR Newswire)
28.06.22	Astellas, Sutro Collaborate To Advance Novel Immunostimulatory Antibody-Drug Conjugates (RTTNews)
28.06.22	Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs) (PR Newswire)
27.06.22	FDA Places Clinical Hold On Astellas' Phase 1/2 Trial Of AT845 In Late-Onset Pompe Disease (RTTNews)
27.06.22	Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease (PR Newswire)
24.06.22	Astellas Pharma Submits Fezolinetant NDA To FDA (RTTNews)
24.06.22	Astellas Submits Fezolinetant New Drug Application to U.S. FDA (PR Newswire)
08.06.22	Astellas Celebrates the Opening of Its New Large-Scale Gene Therapy Manufacturing Facility in North Carolina (PR Newswire)
01.06.22	Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology (PR Newswire)
12.05.22	Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress (PR Newswire)
05.05.22	Astellas to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1™ Trial of Fezolinetant in Oral Session at the American College of Obstetricians and Gynecologists Annual Meeting (PR Newswire)
27.04.22	Astellas Pharma FY21 Core Profit Decreases; Revenue Up 3.7% (RTTNews)
27.04.22	MÄRKTE ASIEN/Tokio und Seoul schwach - Erholungsrally in Schanghai (Dow Jones)
26.04.22	Ausblick: Astellas Pharma stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
25.04.22	MÄRKTE ASIEN/Sehr schwach - Kursdebakel in Schanghai (Dow Jones)
25.04.22	University Of Tokyo, Astellas Pharma Enter Second Phase Of Collaboration - Quick Facts (RTTNews)
25.04.22	University of Tokyo, Astellas Enter Second Phase of Strategic Partnership for Co-creation of Innovative New Medicines and Medical Solutions (PR Newswire)
13.04.22	European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer (PR Newswire)
12.04.22	Erste Schätzungen: Astellas Pharma gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
15.03.22	Astellas : Phase 3 Study Of Fezolinetant On VMS Associated With Menopause Did Not Show Efficacy (RTTNews)
15.03.22	Astellas Announces Topline 12-week Results from Phase 3 Study of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Women in Asia (PR Newswire)
07.03.22	Astellas Reports Positive Results From Phase 3 Study Of Fezolinetant On Vasomotor Symptoms (RTTNews)
07.03.22	Astellas Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant which Inform Future Regulatory Filings for the Treatment of Vasomotor Symptoms Associated with Menopause (PR Newswire)
28.02.22	Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer (PR Newswire)
14.02.22	Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy (PR Newswire)
08.02.22	Astellas Pharma Announces Positive Data From Study Of AT845 In Adults With Late-Onset Pompe Disease (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	4’059.00	2.92 %	K V
Logitech Intl	94.36	2.03 %	K V
Part Grp Hldg	1’422.50	1.07 %	K V
Sika	242.10	0.71 %	K V
Holcim	98.62	0.39 %	K V
Roche Hldg G	294.50	-1.11 %	K V
Kuehne+Nagel Int	209.20	-1.13 %	K V
Nestle	82.48	-1.43 %	K V
Swisscom	499.80	-2.00 %	K V
Novartis	95.37	-2.46 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Astellas Pharma Inc Unsponsored American Deposit Receipt Repr 1-4 Sh

Aktien Top/Flop

Meistgelesene Nachrichten